nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—FER—medulla oblongata—meningioma	0.00198	0.00508	CbGeAlD
Bosutinib—EPHA5—medulla oblongata—meningioma	0.00198	0.00508	CbGeAlD
Bosutinib—ALK—medulla oblongata—meningioma	0.00198	0.00508	CbGeAlD
Bosutinib—PKMYT1—cerebellum—meningioma	0.00198	0.00508	CbGeAlD
Bosutinib—PLK2—spinal cord—meningioma	0.00195	0.00501	CbGeAlD
Bosutinib—DSTYK—cerebellum—meningioma	0.00193	0.00496	CbGeAlD
Bosutinib—CLK3—cerebellum—meningioma	0.00193	0.00496	CbGeAlD
Bosutinib—BTK—medulla oblongata—meningioma	0.00193	0.00495	CbGeAlD
Bosutinib—MAST1—brain—meningioma	0.0019	0.00488	CbGeAlD
Bosutinib—PHKG1—cerebellum—meningioma	0.00189	0.00484	CbGeAlD
Bosutinib—CASK—cerebellum—meningioma	0.00189	0.00484	CbGeAlD
Bosutinib—MAP4K2—medulla oblongata—meningioma	0.00188	0.00481	CbGeAlD
Bosutinib—EIF2AK1—cerebellum—meningioma	0.00187	0.00479	CbGeAlD
Bosutinib—ERBB4—medulla oblongata—meningioma	0.00185	0.00475	CbGeAlD
Bosutinib—EPHA8—cerebellum—meningioma	0.00181	0.00464	CbGeAlD
Bosutinib—FYN—brainstem—meningioma	0.00181	0.00463	CbGeAlD
Bosutinib—TNIK—cerebellum—meningioma	0.00178	0.00455	CbGeAlD
Bosutinib—BMPR2—medulla oblongata—meningioma	0.00177	0.00455	CbGeAlD
Bosutinib—FER—spinal cord—meningioma	0.00177	0.00453	CbGeAlD
Bosutinib—TYRO3—spinal cord—meningioma	0.00177	0.00453	CbGeAlD
Bosutinib—EPHA5—spinal cord—meningioma	0.00177	0.00453	CbGeAlD
Bosutinib—STK36—medulla oblongata—meningioma	0.00176	0.00452	CbGeAlD
Bosutinib—STK26—cerebellum—meningioma	0.00174	0.00447	CbGeAlD
Bosutinib—BTK—spinal cord—meningioma	0.00172	0.00442	CbGeAlD
Bosutinib—MAP4K4—medulla oblongata—meningioma	0.00171	0.00438	CbGeAlD
Bosutinib—BCR—medulla oblongata—meningioma	0.0017	0.00435	CbGeAlD
Bosutinib—TLK1—brain—meningioma	0.0017	0.00435	CbGeAlD
Bosutinib—MAP3K12—medulla oblongata—meningioma	0.00168	0.00432	CbGeAlD
Bosutinib—PRKCQ—brain—meningioma	0.00167	0.00429	CbGeAlD
Bosutinib—WEE1—cerebellum—meningioma	0.00167	0.00428	CbGeAlD
Bosutinib—DMPK—cerebellum—meningioma	0.00167	0.00428	CbGeAlD
Bosutinib—ERBB4—spinal cord—meningioma	0.00165	0.00423	CbGeAlD
Bosutinib—SIK2—brain—meningioma	0.00165	0.00423	CbGeAlD
Bosutinib—STK33—brain—meningioma	0.00165	0.00423	CbGeAlD
Bosutinib—CSK—medulla oblongata—meningioma	0.00164	0.0042	CbGeAlD
Bosutinib—CSNK1A1—medulla oblongata—meningioma	0.00163	0.00418	CbGeAlD
Bosutinib—HCK—medulla oblongata—meningioma	0.00162	0.00415	CbGeAlD
Bosutinib—CLK1—medulla oblongata—meningioma	0.00162	0.00415	CbGeAlD
Bosutinib—TAOK3—brainstem—meningioma	0.00161	0.00413	CbGeAlD
Bosutinib—PKMYT1—brain—meningioma	0.00161	0.00412	CbGeAlD
Bosutinib—STK25—cerebellum—meningioma	0.00159	0.00409	CbGeAlD
Bosutinib—CAMK2G—medulla oblongata—meningioma	0.00159	0.00407	CbGeAlD
Bosutinib—LRRK2—medulla oblongata—meningioma	0.00157	0.00404	CbGeAlD
Bosutinib—EPHB3—spinal cord—meningioma	0.00157	0.00403	CbGeAlD
Bosutinib—DSTYK—brain—meningioma	0.00157	0.00402	CbGeAlD
Bosutinib—CLK3—brain—meningioma	0.00157	0.00402	CbGeAlD
Bosutinib—HIPK4—brain—meningioma	0.00155	0.00398	CbGeAlD
Bosutinib—PLK2—cerebellum—meningioma	0.00155	0.00397	CbGeAlD
Bosutinib—SIK3—cerebellum—meningioma	0.00154	0.00395	CbGeAlD
Bosutinib—EPHB2—brain—meningioma	0.00153	0.00393	CbGeAlD
Bosutinib—CASK—brain—meningioma	0.00153	0.00393	CbGeAlD
Bosutinib—PHKG1—brain—meningioma	0.00153	0.00393	CbGeAlD
Bosutinib—MAP4K4—spinal cord—meningioma	0.00152	0.00391	CbGeAlD
Bosutinib—EIF2AK1—brain—meningioma	0.00152	0.00389	CbGeAlD
Bosutinib—BCR—spinal cord—meningioma	0.00151	0.00388	CbGeAlD
Bosutinib—CSNK1E—medulla oblongata—meningioma	0.00151	0.00387	CbGeAlD
Bosutinib—MAP3K12—spinal cord—meningioma	0.0015	0.00385	CbGeAlD
Bosutinib—SRMS—brain—meningioma	0.0015	0.00385	CbGeAlD
Bosutinib—SIK1—medulla oblongata—meningioma	0.00149	0.00381	CbGeAlD
Bosutinib—IRAK4—medulla oblongata—meningioma	0.00149	0.00381	CbGeAlD
Bosutinib—STK4—cerebellum—meningioma	0.00148	0.0038	CbGeAlD
Bosutinib—MAP2K1—spinal cord—meningioma	0.00147	0.00377	CbGeAlD
Bosutinib—EPHA4—medulla oblongata—meningioma	0.00147	0.00377	CbGeAlD
Bosutinib—VRK2—brain—meningioma	0.00147	0.00377	CbGeAlD
Bosutinib—EPHA8—brain—meningioma	0.00147	0.00377	CbGeAlD
Bosutinib—FES—brain—meningioma	0.00147	0.00377	CbGeAlD
Bosutinib—CAMK1D—cerebellum—meningioma	0.00146	0.00376	CbGeAlD
Bosutinib—CSK—spinal cord—meningioma	0.00146	0.00375	CbGeAlD
Bosutinib—MAP2K2—medulla oblongata—meningioma	0.00145	0.00373	CbGeAlD
Bosutinib—ULK3—medulla oblongata—meningioma	0.00145	0.00373	CbGeAlD
Bosutinib—CSNK1A1—spinal cord—meningioma	0.00145	0.00372	CbGeAlD
Bosutinib—STK24—cerebellum—meningioma	0.00145	0.00371	CbGeAlD
Bosutinib—HCK—spinal cord—meningioma	0.00144	0.0037	CbGeAlD
Bosutinib—CLK1—spinal cord—meningioma	0.00144	0.0037	CbGeAlD
Bosutinib—SYK—brain—meningioma	0.00144	0.0037	CbGeAlD
Bosutinib—TNIK—brain—meningioma	0.00144	0.0037	CbGeAlD
Bosutinib—MAP2K5—brainstem—meningioma	0.00144	0.0037	CbGeAlD
Bosutinib—MAP3K7—medulla oblongata—meningioma	0.00143	0.00366	CbGeAlD
Bosutinib—CDK2—brain—meningioma	0.00143	0.00366	CbGeAlD
Bosutinib—CAMK2G—spinal cord—meningioma	0.00142	0.00363	CbGeAlD
Bosutinib—BMP2K—spinal cord—meningioma	0.00142	0.00363	CbGeAlD
Bosutinib—STK26—brain—meningioma	0.00142	0.00363	CbGeAlD
Bosutinib—TBK1—medulla oblongata—meningioma	0.00141	0.00362	CbGeAlD
Bosutinib—LRRK2—spinal cord—meningioma	0.0014	0.0036	CbGeAlD
Bosutinib—FER—cerebellum—meningioma	0.0014	0.00359	CbGeAlD
Bosutinib—EPHA5—cerebellum—meningioma	0.0014	0.00359	CbGeAlD
Bosutinib—TYRO3—cerebellum—meningioma	0.0014	0.00359	CbGeAlD
Bosutinib—CHEK2—brain—meningioma	0.00137	0.00351	CbGeAlD
Bosutinib—RPS6KB1—medulla oblongata—meningioma	0.00136	0.00348	CbGeAlD
Bosutinib—WEE1—brain—meningioma	0.00136	0.00348	CbGeAlD
Bosutinib—DMPK—brain—meningioma	0.00136	0.00348	CbGeAlD
Bosutinib—CSNK1E—spinal cord—meningioma	0.00135	0.00345	CbGeAlD
Bosutinib—TNK2—cerebellum—meningioma	0.00135	0.00345	CbGeAlD
Bosutinib—AXL—medulla oblongata—meningioma	0.00135	0.00345	CbGeAlD
Bosutinib—MAP4K2—cerebellum—meningioma	0.00133	0.0034	CbGeAlD
Bosutinib—IRAK4—spinal cord—meningioma	0.00132	0.0034	CbGeAlD
Bosutinib—SIK1—spinal cord—meningioma	0.00132	0.0034	CbGeAlD
Bosutinib—ERBB4—cerebellum—meningioma	0.00131	0.00336	CbGeAlD
Bosutinib—STK3—cerebellum—meningioma	0.00131	0.00336	CbGeAlD
Bosutinib—ERBB3—spinal cord—meningioma	0.0013	0.00333	CbGeAlD
Bosutinib—MAP2K2—spinal cord—meningioma	0.0013	0.00332	CbGeAlD
Bosutinib—ULK3—spinal cord—meningioma	0.0013	0.00332	CbGeAlD
Bosutinib—SLK—medulla oblongata—meningioma	0.00129	0.00332	CbGeAlD
Bosutinib—STK25—brain—meningioma	0.00129	0.00332	CbGeAlD
Bosutinib—EPHB4—medulla oblongata—meningioma	0.00129	0.0033	CbGeAlD
Bosutinib—EPHA3—brain—meningioma	0.00129	0.0033	CbGeAlD
Bosutinib—MAP3K7—spinal cord—meningioma	0.00127	0.00327	CbGeAlD
Bosutinib—PTK2—spinal cord—meningioma	0.00126	0.00323	CbGeAlD
Bosutinib—TBK1—spinal cord—meningioma	0.00126	0.00323	CbGeAlD
Bosutinib—FYN—medulla oblongata—meningioma	0.00126	0.00323	CbGeAlD
Bosutinib—PLK2—brain—meningioma	0.00126	0.00323	CbGeAlD
Bosutinib—BMPR2—cerebellum—meningioma	0.00125	0.00322	CbGeAlD
Bosutinib—SIK3—brain—meningioma	0.00125	0.00321	CbGeAlD
Bosutinib—STK36—cerebellum—meningioma	0.00124	0.00319	CbGeAlD
Bosutinib—EPHB3—cerebellum—meningioma	0.00124	0.00319	CbGeAlD
Bosutinib—MERTK—cerebellum—meningioma	0.00123	0.00316	CbGeAlD
Bosutinib—MAP4K5—medulla oblongata—meningioma	0.00123	0.00316	CbGeAlD
Bosutinib—MAP3K3—medulla oblongata—meningioma	0.00123	0.00316	CbGeAlD
Bosutinib—RPS6KB1—spinal cord—meningioma	0.00121	0.00311	CbGeAlD
Bosutinib—MAP4K4—cerebellum—meningioma	0.00121	0.0031	CbGeAlD
Bosutinib—STK4—brain—meningioma	0.0012	0.00309	CbGeAlD
Bosutinib—AXL—spinal cord—meningioma	0.0012	0.00308	CbGeAlD
Bosutinib—NUAK2—cerebellum—meningioma	0.0012	0.00308	CbGeAlD
Bosutinib—BCR—cerebellum—meningioma	0.0012	0.00308	CbGeAlD
Bosutinib—MAP3K12—cerebellum—meningioma	0.00119	0.00305	CbGeAlD
Bosutinib—CAMK1D—brain—meningioma	0.00119	0.00305	CbGeAlD
Bosutinib—STK24—brain—meningioma	0.00118	0.00302	CbGeAlD
Bosutinib—STK35—cerebellum—meningioma	0.00117	0.00299	CbGeAlD
Bosutinib—MAP2K1—cerebellum—meningioma	0.00117	0.00299	CbGeAlD
Bosutinib—CSK—cerebellum—meningioma	0.00116	0.00297	CbGeAlD
Bosutinib—SLK—spinal cord—meningioma	0.00115	0.00296	CbGeAlD
Bosutinib—CSNK1A1—cerebellum—meningioma	0.00115	0.00295	CbGeAlD
Bosutinib—EPHB4—spinal cord—meningioma	0.00115	0.00294	CbGeAlD
Bosutinib—CLK1—cerebellum—meningioma	0.00114	0.00293	CbGeAlD
Bosutinib—FER—brain—meningioma	0.00114	0.00292	CbGeAlD
Bosutinib—ALK—brain—meningioma	0.00114	0.00292	CbGeAlD
Bosutinib—EPHA5—brain—meningioma	0.00114	0.00292	CbGeAlD
Bosutinib—TYRO3—brain—meningioma	0.00114	0.00292	CbGeAlD
Bosutinib—ABL2—cerebellum—meningioma	0.00114	0.00292	CbGeAlD
Bosutinib—YES1—medulla oblongata—meningioma	0.00114	0.00291	CbGeAlD
Bosutinib—LYN—brain—meningioma	0.00113	0.0029	CbGeAlD
Bosutinib—CAMK2G—cerebellum—meningioma	0.00112	0.00288	CbGeAlD
Bosutinib—BMP2K—cerebellum—meningioma	0.00112	0.00288	CbGeAlD
Bosutinib—FYN—spinal cord—meningioma	0.00112	0.00288	CbGeAlD
Bosutinib—TAOK3—medulla oblongata—meningioma	0.00112	0.00288	CbGeAlD
Bosutinib—MAP4K1—brain—meningioma	0.00111	0.00286	CbGeAlD
Bosutinib—MAP3K19—brain—meningioma	0.00111	0.00286	CbGeAlD
Bosutinib—LRRK2—cerebellum—meningioma	0.00111	0.00285	CbGeAlD
Bosutinib—ABL1—brainstem—meningioma	0.00111	0.00285	CbGeAlD
Bosutinib—EGFR—cerebellum—meningioma	0.00111	0.00285	CbGeAlD
Bosutinib—BTK—brain—meningioma	0.00111	0.00284	CbGeAlD
Bosutinib—MAP4K5—spinal cord—meningioma	0.0011	0.00281	CbGeAlD
Bosutinib—MAP3K3—spinal cord—meningioma	0.0011	0.00281	CbGeAlD
Bosutinib—TNK2—brain—meningioma	0.00109	0.0028	CbGeAlD
Bosutinib—PTK2B—cerebellum—meningioma	0.00108	0.00278	CbGeAlD
Bosutinib—MAP4K2—brain—meningioma	0.00108	0.00276	CbGeAlD
Bosutinib—CSNK1E—cerebellum—meningioma	0.00107	0.00274	CbGeAlD
Bosutinib—STK3—brain—meningioma	0.00106	0.00273	CbGeAlD
Bosutinib—ERBB4—brain—meningioma	0.00106	0.00273	CbGeAlD
Bosutinib—SIK1—cerebellum—meningioma	0.00105	0.00269	CbGeAlD
Bosutinib—IRAK4—cerebellum—meningioma	0.00105	0.00269	CbGeAlD
Bosutinib—ROCK1—brain—meningioma	0.00105	0.00269	CbGeAlD
Bosutinib—EPHA4—cerebellum—meningioma	0.00104	0.00267	CbGeAlD
Bosutinib—ERBB3—cerebellum—meningioma	0.00103	0.00264	CbGeAlD
Bosutinib—ULK3—cerebellum—meningioma	0.00103	0.00263	CbGeAlD
Bosutinib—MAP2K2—cerebellum—meningioma	0.00103	0.00263	CbGeAlD
Bosutinib—MAP3K2—cerebellum—meningioma	0.00102	0.00262	CbGeAlD
Bosutinib—BMPR2—brain—meningioma	0.00102	0.00261	CbGeAlD
Bosutinib—YES1—spinal cord—meningioma	0.00101	0.0026	CbGeAlD
Bosutinib—STK36—brain—meningioma	0.00101	0.00259	CbGeAlD
Bosutinib—EPHB3—brain—meningioma	0.00101	0.00259	CbGeAlD
Bosutinib—MAP3K7—cerebellum—meningioma	0.00101	0.00259	CbGeAlD
Bosutinib—MAP2K5—medulla oblongata—meningioma	0.00101	0.00258	CbGeAlD
Bosutinib—TAOK3—spinal cord—meningioma	0.001	0.00257	CbGeAlD
Bosutinib—MERTK—brain—meningioma	0.001	0.00256	CbGeAlD
Bosutinib—PTK2—cerebellum—meningioma	0.000999	0.00256	CbGeAlD
Bosutinib—TBK1—cerebellum—meningioma	0.000999	0.00256	CbGeAlD
Bosutinib—CSF1R—medulla oblongata—meningioma	0.000981	0.00252	CbGeAlD
Bosutinib—MAP4K4—brain—meningioma	0.000981	0.00252	CbGeAlD
Bosutinib—IRAK1—cerebellum—meningioma	0.000979	0.00251	CbGeAlD
Bosutinib—SRC—spinal cord—meningioma	0.000975	0.0025	CbGeAlD
Bosutinib—BCR—brain—meningioma	0.000974	0.0025	CbGeAlD
Bosutinib—NUAK2—brain—meningioma	0.000974	0.0025	CbGeAlD
Bosutinib—MAP3K12—brain—meningioma	0.000967	0.00248	CbGeAlD
Bosutinib—RPS6KB1—cerebellum—meningioma	0.000961	0.00246	CbGeAlD
Bosutinib—AXL—cerebellum—meningioma	0.000951	0.00244	CbGeAlD
Bosutinib—MAP2K1—brain—meningioma	0.000948	0.00243	CbGeAlD
Bosutinib—STK35—brain—meningioma	0.000948	0.00243	CbGeAlD
Bosutinib—CSK—brain—meningioma	0.000941	0.00241	CbGeAlD
Bosutinib—CSNK1A1—brain—meningioma	0.000935	0.0024	CbGeAlD
Bosutinib—CLK1—brain—meningioma	0.000929	0.00238	CbGeAlD
Bosutinib—HCK—brain—meningioma	0.000929	0.00238	CbGeAlD
Bosutinib—ABL2—brain—meningioma	0.000923	0.00237	CbGeAlD
Bosutinib—SLK—cerebellum—meningioma	0.000915	0.00235	CbGeAlD
Bosutinib—CAMK2G—brain—meningioma	0.000912	0.00234	CbGeAlD
Bosutinib—BMP2K—brain—meningioma	0.000912	0.00234	CbGeAlD
Bosutinib—EPHB4—cerebellum—meningioma	0.000909	0.00233	CbGeAlD
Bosutinib—LRRK2—brain—meningioma	0.000904	0.00232	CbGeAlD
Bosutinib—EGFR—brain—meningioma	0.000901	0.00231	CbGeAlD
Bosutinib—MAP2K5—spinal cord—meningioma	0.000897	0.0023	CbGeAlD
Bosutinib—FYN—cerebellum—meningioma	0.00089	0.00228	CbGeAlD
Bosutinib—PTK2B—brain—meningioma	0.000881	0.00226	CbGeAlD
Bosutinib—CSF1R—spinal cord—meningioma	0.000875	0.00224	CbGeAlD
Bosutinib—PDGFRB—medulla oblongata—meningioma	0.00087	0.00223	CbGeAlD
Bosutinib—MAP3K3—cerebellum—meningioma	0.00087	0.00223	CbGeAlD
Bosutinib—MAP4K5—cerebellum—meningioma	0.00087	0.00223	CbGeAlD
Bosutinib—CSNK1E—brain—meningioma	0.000867	0.00222	CbGeAlD
Bosutinib—SIK1—brain—meningioma	0.000853	0.00219	CbGeAlD
Bosutinib—IRAK4—brain—meningioma	0.000853	0.00219	CbGeAlD
Bosutinib—EPHA4—brain—meningioma	0.000845	0.00217	CbGeAlD
Bosutinib—ERBB3—brain—meningioma	0.000836	0.00214	CbGeAlD
Bosutinib—MAP2K2—brain—meningioma	0.000834	0.00214	CbGeAlD
Bosutinib—ULK3—brain—meningioma	0.000834	0.00214	CbGeAlD
Bosutinib—MAP3K2—brain—meningioma	0.000828	0.00212	CbGeAlD
Bosutinib—MAP3K7—brain—meningioma	0.00082	0.0021	CbGeAlD
Bosutinib—TBK1—brain—meningioma	0.000811	0.00208	CbGeAlD
Bosutinib—PTK2—brain—meningioma	0.000811	0.00208	CbGeAlD
Bosutinib—YES1—cerebellum—meningioma	0.000803	0.00206	CbGeAlD
Bosutinib—STK10—cerebellum—meningioma	0.000796	0.00204	CbGeAlD
Bosutinib—IRAK1—brain—meningioma	0.000795	0.00204	CbGeAlD
Bosutinib—TAOK3—cerebellum—meningioma	0.000793	0.00203	CbGeAlD
Bosutinib—RPS6KB1—brain—meningioma	0.00078	0.002	CbGeAlD
Bosutinib—PDGFRB—spinal cord—meningioma	0.000776	0.00199	CbGeAlD
Bosutinib—ABL1—medulla oblongata—meningioma	0.000776	0.00199	CbGeAlD
Bosutinib—FGR—brain—meningioma	0.000776	0.00199	CbGeAlD
Bosutinib—SRC—cerebellum—meningioma	0.000773	0.00198	CbGeAlD
Bosutinib—AXL—brain—meningioma	0.000772	0.00198	CbGeAlD
Bosutinib—SLK—brain—meningioma	0.000744	0.00191	CbGeAlD
Bosutinib—EPHB4—brain—meningioma	0.000738	0.00189	CbGeAlD
Bosutinib—EPHA2—brain—meningioma	0.000724	0.00186	CbGeAlD
Bosutinib—FYN—brain—meningioma	0.000723	0.00185	CbGeAlD
Bosutinib—MAP2K5—cerebellum—meningioma	0.000711	0.00182	CbGeAlD
Bosutinib—MAP3K3—brain—meningioma	0.000707	0.00181	CbGeAlD
Bosutinib—MAP4K5—brain—meningioma	0.000707	0.00181	CbGeAlD
Bosutinib—CSF1R—cerebellum—meningioma	0.000694	0.00178	CbGeAlD
Bosutinib—ABL1—spinal cord—meningioma	0.000692	0.00177	CbGeAlD
Bosutinib—YES1—brain—meningioma	0.000652	0.00167	CbGeAlD
Bosutinib—STK10—brain—meningioma	0.000647	0.00166	CbGeAlD
Bosutinib—TAOK3—brain—meningioma	0.000644	0.00165	CbGeAlD
Bosutinib—SRC—brain—meningioma	0.000628	0.00161	CbGeAlD
Bosutinib—PDGFRB—cerebellum—meningioma	0.000615	0.00158	CbGeAlD
Bosutinib—MAP2K5—brain—meningioma	0.000577	0.00148	CbGeAlD
Bosutinib—CSF1R—brain—meningioma	0.000564	0.00145	CbGeAlD
Bosutinib—ABL1—cerebellum—meningioma	0.000548	0.00141	CbGeAlD
Bosutinib—PDGFRB—brain—meningioma	0.0005	0.00128	CbGeAlD
Bosutinib—ABL1—brain—meningioma	0.000445	0.00114	CbGeAlD
Bosutinib—ABCB1—medulla oblongata—meningioma	0.000241	0.000619	CbGeAlD
Bosutinib—ABCB1—spinal cord—meningioma	0.000215	0.000552	CbGeAlD
Bosutinib—ABCB1—cerebellum—meningioma	0.000171	0.000437	CbGeAlD
Bosutinib—ABCB1—brain—meningioma	0.000139	0.000355	CbGeAlD
Bosutinib—LCK—Immune System—PDGFB—meningioma	3.09e-05	5.07e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Immune System—AKT1—meningioma	3.09e-05	5.06e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling by NGF—AKT1—meningioma	3.07e-05	5.03e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—PTEN—meningioma	3.04e-05	4.99e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—PTEN—meningioma	3.04e-05	4.98e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—ERBB2—meningioma	3.03e-05	4.97e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PGR—meningioma	3.03e-05	4.96e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—ERBB2—meningioma	3.03e-05	4.96e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—PTEN—meningioma	3.03e-05	4.96e-05	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—AKT1—meningioma	2.99e-05	4.9e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HES1—meningioma	2.99e-05	4.9e-05	CbGpPWpGaD
Bosutinib—CSK—Immune System—AKT1—meningioma	2.98e-05	4.89e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—PDGFB—meningioma	2.96e-05	4.86e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—HES1—meningioma	2.96e-05	4.85e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—PTEN—meningioma	2.93e-05	4.81e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PDGFB—meningioma	2.92e-05	4.79e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—PTEN—meningioma	2.92e-05	4.78e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HES1—meningioma	2.91e-05	4.78e-05	CbGpPWpGaD
Bosutinib—PTK2—Innate Immune System—AKT1—meningioma	2.9e-05	4.76e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—PTEN—meningioma	2.89e-05	4.74e-05	CbGpPWpGaD
Bosutinib—YES1—Innate Immune System—AKT1—meningioma	2.86e-05	4.69e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—PDGFB—meningioma	2.86e-05	4.68e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HES1—meningioma	2.85e-05	4.68e-05	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—AKT1—meningioma	2.85e-05	4.68e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Disease—AKT1—meningioma	2.85e-05	4.67e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Disease—AKT1—meningioma	2.85e-05	4.67e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—ERBB2—meningioma	2.84e-05	4.65e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—TP53—meningioma	2.83e-05	4.64e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HES1—meningioma	2.81e-05	4.61e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—TP53—meningioma	2.81e-05	4.6e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—PTEN—meningioma	2.8e-05	4.58e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—TP53—meningioma	2.8e-05	4.58e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HES1—meningioma	2.79e-05	4.58e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—ERBB2—meningioma	2.79e-05	4.58e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—TP53—meningioma	2.76e-05	4.53e-05	CbGpPWpGaD
Bosutinib—CSK—Disease—AKT1—meningioma	2.75e-05	4.51e-05	CbGpPWpGaD
Bosutinib—YES1—Adaptive Immune System—AKT1—meningioma	2.75e-05	4.51e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—PTEN—meningioma	2.74e-05	4.5e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—PDGFB—meningioma	2.74e-05	4.49e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—AKT1—meningioma	2.74e-05	4.48e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling by NGF—AKT1—meningioma	2.72e-05	4.45e-05	CbGpPWpGaD
Bosutinib—IRAK1—Innate Immune System—AKT1—meningioma	2.72e-05	4.45e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—ERBB2—meningioma	2.69e-05	4.41e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—PTEN—meningioma	2.69e-05	4.41e-05	CbGpPWpGaD
Bosutinib—TBK1—Immune System—AKT1—meningioma	2.67e-05	4.38e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—ERBB2—meningioma	2.65e-05	4.34e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—TSHB—meningioma	2.63e-05	4.31e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—meningioma	2.63e-05	4.31e-05	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—AKT1—meningioma	2.62e-05	4.3e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—ERBB2—meningioma	2.59e-05	4.25e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—ERBB2—meningioma	2.59e-05	4.25e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—ERBB2—meningioma	2.58e-05	4.24e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—PTEN—meningioma	2.58e-05	4.24e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—PTEN—meningioma	2.58e-05	4.23e-05	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—AKT1—meningioma	2.56e-05	4.2e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—AKT1—meningioma	2.56e-05	4.19e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PDGFB—meningioma	2.55e-05	4.19e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—ERBB2—meningioma	2.53e-05	4.15e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—AKT1—meningioma	2.53e-05	4.15e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—PDGFB—meningioma	2.53e-05	4.15e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—ERBB2—meningioma	2.52e-05	4.13e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALAD—meningioma	2.51e-05	4.12e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—ERBB2—meningioma	2.5e-05	4.1e-05	CbGpPWpGaD
Bosutinib—BTK—Immune System—AKT1—meningioma	2.49e-05	4.09e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PDGFB—meningioma	2.49e-05	4.09e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—ERBB2—meningioma	2.49e-05	4.08e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—ERBB2—meningioma	2.48e-05	4.06e-05	CbGpPWpGaD
Bosutinib—ROCK1—GPCR downstream signaling—AKT1—meningioma	2.47e-05	4.04e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Adaptive Immune System—AKT1—meningioma	2.46e-05	4.02e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—ERBB2—meningioma	2.45e-05	4.01e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PDGFB—meningioma	2.44e-05	4e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HES1—meningioma	2.43e-05	3.98e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—PTEN—meningioma	2.42e-05	3.96e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—AKT1—meningioma	2.42e-05	3.96e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—TP53—meningioma	2.41e-05	3.95e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—AKT1—meningioma	2.41e-05	3.94e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PDGFB—meningioma	2.4e-05	3.94e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—AKT1—meningioma	2.39e-05	3.92e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PDGFB—meningioma	2.39e-05	3.92e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—ERBB2—meningioma	2.39e-05	3.91e-05	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—AKT1—meningioma	2.38e-05	3.91e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—PTEN—meningioma	2.38e-05	3.91e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—AKT1—meningioma	2.38e-05	3.9e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—AKT1—meningioma	2.37e-05	3.89e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—AKT1—meningioma	2.37e-05	3.88e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—TP53—meningioma	2.36e-05	3.87e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—TP53—meningioma	2.36e-05	3.87e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—AKT1—meningioma	2.36e-05	3.87e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HES1—meningioma	2.34e-05	3.83e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—AKT1—meningioma	2.33e-05	3.83e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—AKT1—meningioma	2.3e-05	3.77e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TP53—meningioma	2.3e-05	3.77e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—ERBB2—meningioma	2.3e-05	3.77e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—PTEN—meningioma	2.3e-05	3.76e-05	CbGpPWpGaD
Bosutinib—HCK—Immune System—AKT1—meningioma	2.29e-05	3.75e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—ERBB2—meningioma	2.29e-05	3.75e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TP53—meningioma	2.28e-05	3.74e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—PTEN—meningioma	2.26e-05	3.7e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—AKT1—meningioma	2.24e-05	3.67e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—AKT1—meningioma	2.23e-05	3.66e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—ERBB2—meningioma	2.22e-05	3.65e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	2.22e-05	3.64e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—PTEN—meningioma	2.21e-05	3.62e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—PTEN—meningioma	2.21e-05	3.62e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—PTEN—meningioma	2.2e-05	3.61e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—ERBB2—meningioma	2.19e-05	3.6e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—AKT1—meningioma	2.18e-05	3.57e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—PTEN—meningioma	2.16e-05	3.54e-05	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—AKT1—meningioma	2.16e-05	3.53e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—ERBB2—meningioma	2.15e-05	3.53e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—PTEN—meningioma	2.15e-05	3.52e-05	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—AKT1—meningioma	2.14e-05	3.5e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—PTEN—meningioma	2.13e-05	3.49e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—AKT1—meningioma	2.13e-05	3.48e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—PTEN—meningioma	2.12e-05	3.48e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—AKT1—meningioma	2.12e-05	3.48e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—PTEN—meningioma	2.11e-05	3.46e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—AKT1—meningioma	2.11e-05	3.46e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—AKT1—meningioma	2.1e-05	3.45e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—AKT1—meningioma	2.09e-05	3.43e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—AKT1—meningioma	2.09e-05	3.43e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PTEN—meningioma	2.09e-05	3.42e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—ERBB2—meningioma	2.08e-05	3.41e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PDGFB—meningioma	2.08e-05	3.4e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—ERBB2—meningioma	2.07e-05	3.4e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—AKT1—meningioma	2.07e-05	3.4e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HES1—meningioma	2.07e-05	3.39e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—AKT1—meningioma	2.07e-05	3.39e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—AKT1—meningioma	2.06e-05	3.37e-05	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—AKT1—meningioma	2.05e-05	3.36e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—meningioma	2.04e-05	3.34e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PTEN—meningioma	2.03e-05	3.34e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—AKT1—meningioma	2.03e-05	3.33e-05	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—AKT1—meningioma	2.02e-05	3.31e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PDGFB—meningioma	2e-05	3.28e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—AKT1—meningioma	2e-05	3.27e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—AKT1—meningioma	2e-05	3.27e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—AKT1—meningioma	1.99e-05	3.26e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—ERBB2—meningioma	1.99e-05	3.26e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—PTEN—meningioma	1.96e-05	3.21e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—ERBB2—meningioma	1.96e-05	3.21e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PTEN—meningioma	1.95e-05	3.2e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—AKT1—meningioma	1.94e-05	3.19e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—AKT1—meningioma	1.93e-05	3.16e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—ERBB2—meningioma	1.91e-05	3.14e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—meningioma	1.91e-05	3.13e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—AKT1—meningioma	1.9e-05	3.11e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PTEN—meningioma	1.9e-05	3.11e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PTEN—meningioma	1.87e-05	3.07e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—ERBB2—meningioma	1.84e-05	3.01e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PTEN—meningioma	1.84e-05	3.01e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—AKT1—meningioma	1.82e-05	2.98e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PTEN—meningioma	1.77e-05	2.91e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PDGFB—meningioma	1.77e-05	2.9e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—PTEN—meningioma	1.77e-05	2.9e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—AKT1—meningioma	1.75e-05	2.88e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—AKT1—meningioma	1.75e-05	2.88e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—AKT1—meningioma	1.75e-05	2.87e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—AKT1—meningioma	1.74e-05	2.86e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—AKT1—meningioma	1.72e-05	2.82e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—ERBB2—meningioma	1.71e-05	2.81e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—ERBB2—meningioma	1.7e-05	2.78e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—PTEN—meningioma	1.69e-05	2.78e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—AKT1—meningioma	1.69e-05	2.77e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—AKT1—meningioma	1.68e-05	2.75e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—ERBB2—meningioma	1.67e-05	2.74e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PTEN—meningioma	1.67e-05	2.74e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—AKT1—meningioma	1.67e-05	2.73e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—meningioma	1.65e-05	2.7e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—ERBB2—meningioma	1.64e-05	2.68e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—PTEN—meningioma	1.63e-05	2.68e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—meningioma	1.63e-05	2.67e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TSHB—meningioma	1.62e-05	2.65e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—AKT1—meningioma	1.61e-05	2.64e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ERBB2—meningioma	1.61e-05	2.64e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ERBB2—meningioma	1.6e-05	2.63e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—AKT1—meningioma	1.58e-05	2.59e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—meningioma	1.57e-05	2.57e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—PTEN—meningioma	1.57e-05	2.57e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—AKT1—meningioma	1.55e-05	2.54e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—meningioma	1.51e-05	2.47e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—meningioma	1.51e-05	2.47e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AKT1—meningioma	1.49e-05	2.44e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—AKT1—meningioma	1.49e-05	2.44e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PTEN—meningioma	1.46e-05	2.39e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—meningioma	1.45e-05	2.38e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—PTEN—meningioma	1.45e-05	2.37e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PTEN—meningioma	1.42e-05	2.34e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—meningioma	1.42e-05	2.33e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PTEN—meningioma	1.4e-05	2.29e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—meningioma	1.39e-05	2.28e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ERBB2—meningioma	1.39e-05	2.28e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PTEN—meningioma	1.37e-05	2.25e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—meningioma	1.37e-05	2.25e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PTEN—meningioma	1.37e-05	2.24e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—meningioma	1.34e-05	2.2e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—meningioma	1.33e-05	2.18e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—meningioma	1.32e-05	2.17e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—meningioma	1.3e-05	2.13e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—meningioma	1.29e-05	2.12e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—meningioma	1.28e-05	2.09e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—meningioma	1.27e-05	2.09e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—meningioma	1.27e-05	2.09e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—meningioma	1.27e-05	2.08e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—meningioma	1.24e-05	2.04e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—meningioma	1.24e-05	2.03e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—meningioma	1.23e-05	2.01e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—meningioma	1.22e-05	2.01e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—meningioma	1.22e-05	2e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—meningioma	1.21e-05	1.98e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—meningioma	1.2e-05	1.97e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—meningioma	1.19e-05	1.95e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—meningioma	1.19e-05	1.94e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—meningioma	1.17e-05	1.92e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—meningioma	1.16e-05	1.9e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—meningioma	1.14e-05	1.87e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—meningioma	1.14e-05	1.87e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—meningioma	1.13e-05	1.85e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—meningioma	1.12e-05	1.84e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—meningioma	1.09e-05	1.79e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—meningioma	1.08e-05	1.77e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—meningioma	1.06e-05	1.73e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—meningioma	1.02e-05	1.68e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—meningioma	1.02e-05	1.67e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—meningioma	1.01e-05	1.66e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—meningioma	9.97e-06	1.63e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—meningioma	9.77e-06	1.6e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—meningioma	9.72e-06	1.59e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—meningioma	9.63e-06	1.58e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—meningioma	9.52e-06	1.56e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—meningioma	9.41e-06	1.54e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—meningioma	9.37e-06	1.54e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—meningioma	9.32e-06	1.53e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—meningioma	9.02e-06	1.48e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—meningioma	8.41e-06	1.38e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—meningioma	8.33e-06	1.37e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—meningioma	8.21e-06	1.35e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—meningioma	8.1e-06	1.33e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—meningioma	8.04e-06	1.32e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—meningioma	7.92e-06	1.3e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—meningioma	7.87e-06	1.29e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—meningioma	7.8e-06	1.28e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—meningioma	7.16e-06	1.17e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—meningioma	6.91e-06	1.13e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—meningioma	6.84e-06	1.12e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—meningioma	6.59e-06	1.08e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—meningioma	5.83e-06	9.56e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—meningioma	4.41e-06	7.23e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—meningioma	4.13e-06	6.77e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—meningioma	2.54e-06	4.17e-06	CbGpPWpGaD
